BTG reports full year product sales ahead of guidance
International healthcare company BTG on Thursday said full year product sales were at the upper end of expectations, with pharmaceuticals delivering double-digit growth, ahead of guidance.
Licensing revenues were broadly flat year-on-year as royalty income was hit by the launch of generic versions of its Zytiga in the US.
Oncology and vascular sales were in line with the board's guidance range of 15% - 17% growth,
“Pharmaceuticals benefited from unusually high sales of DigiFab in the fourth quarter as hospitals replaced product that had expired at a higher rate than expected,” BTG said in a trading statement.
BTG added that it expected to complete its sale to Boston Scientific around the middle of 2019.